awmsg logo



golimumab (Simponi®)


Reference No. 4066

Publication date:
12/06/2019


Appraisal information

golimumab (Simponi®) 45 mg/0.45 ml solution for injection


Company: Janssen-Cilag Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 11/06/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, golimumab (Simponi®) cannot be endorsed for use within NHS Wales in combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with methotrexate
Statement of Advice (SOA)
Download